Modelling and control of HIV dynamics

Computer Methods and Programs in Biomedicine

Volumn 89, Issue 2, 2008, Pages 162-168

  Landi, Alberto ^a   Mazzoldi, Alberto ^a   Andreoni, Chiara ^a   Bianchi, Matteo ^a   Cavallini, Andrea ^a   Laurino, Marco ^a   Ricotti, Leonardo ^a   Iuliano, Rodolfo ^a   Matteoli, Barbara ^a   Ceccherini Nelli, Luca ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Biomedical system; Differential equations; HIV; Numerical simulations; Physiological models

Indexed keywords

COMPUTER SIMULATION; DRUG PRODUCTS; MATHEMATICAL MODELS; VIRUSES;

BIOMEDICAL SYSTEMS; HIV DYNAMICS;

BIOMEDICAL ENGINEERING;

ARTICLE; COMPUTER SIMULATION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; MATHEMATICAL MODEL; PREDICTION; TREATMENT RESPONSE; VIRUS INFECTIVITY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HUMANS; ITALY; MODELS, BIOLOGICAL; MODELS, STATISTICAL; VIRAL LOAD;

EID: 37849009397     PISSN: 01692607     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cmpb.2007.08.003     Document Type: Article

References (25)

1. Wodarz D., and Nowak M.A. Mathematical models of HIV pathogenesis and treatment. BioEssays 24 (2000) 1178-1187
2. Vergu E., Mallet A., and Golmard J.L. A modeling approach to the impact of HIV mutations on the immune system. Comput. Biol. Med. 35 (2005) 1-24
3. Zurakowski R., and Teel A.R. A model predictive control based scheduling method for HIV therapy. J. Theor. Biol. 238 (2006) 368-382
4. Pantaleo G., and Fauci A.S. New concepts in the immunopathogenesis of HIV infection. Annu. Rev. Immunol. 13 (1995) 487-512
5. Finzi D., et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 5 (1999) 512-517
6. Ortega H., and Landrove M.M. A model for continuously mutant HIV-1. Proceedings of the 22nd Annual Engineering and Medicine Biology Society International Conference. Chicago, USA (2000) 1917-1920
7. Di Mascio M. Modeling the long-term control of viremia in HIV-1 infected patients treated with antiretroviral therapy. Math. Biosci. 188 (2004) 47-62
8. Adams B.M., et al. HIV dynamics: modeling, data analysis, and optimal treatment protocols. J. Comput. Appl. Math. 184 (2005) 10-49
9. Brandt M.E., and Chen G. Feedback control of a biodynamical model of HIV-1. IEEE Trans. Biomed. Eng. 48 (2001) 754-759
10. Joly M., and Pinto J.M. Role of mathematical modeling on the optimal control of HIV-1 pathogenesis. AIChE J. 52 (2006) 856-884
11. Wodarz D., and Nowak M.A. Specific therapy regimes could lead to long-term immunological control of HIV. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 14464-14469
12. Craig I., and Xia X. Can HIV/AIDS be controlled?. IEEE Cont. Syst. Mag. (2005) 80-83
13. Quinones-Mateu M.E., et al. A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J. Virol. (2000) 9222-9233
14. Xia X. Estimation of HIV/AIDS parameters. Automatica 39 (2003) 1983-1988
15. Jeffrey A.M., and Xia X. Estimating the viral load response time after HIV chemotherapy. Proceedings of IEEE Africon. Conference, George, South Africa (2002) 77-80
16. Mellors J.W., et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann. Intern. Med. 126 (1997) 946-954
17. Iuliano R., et al. Correlation between plasma HIV-1 RNA levels and the rate of immunologic decline. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol. 14 (1997) 408-414
18. Kaufmann G.R., et al. Impact of early HIV-1 RNA and T-lymphocyte dynamics during primary HIV-1 infection on the subsequent course of HIV-1 RNA levels and CD4+ T-lymphocyte counts in the first year of HIV-1 infection. Sydney Primary HIV Infection Study Group. J. Acquir. Immune Defic. Syndr. 22 (1999) 437-444
19. + T cells with an effector phenotype and control of viral replication. Lancet 362 (2004) 863-866
20. + T effector cells are more frequently detectable in controlled than in progressive HIV-1 infection. PLoS ONE 2 (2007) e321
21. Lowe S.H., Prins J.M., and Lange J.M. Antiretroviral therapy in previously untreated adults infected with the human immunodeficiency virus type I: established and potential determinants of virological outcome. Neth. J. Med. 62 (2004) 424-440
22. Jin X., et al. An antigenic threshold for maintaining human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. Mol. Med. 6 (2000) 803-809
23. Ogg G.S., et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73 (1999) 797-800
24. Wang C., Masho S.W., and Nixon D.E. When to start antiretroviral therapy. Curr. HIV/AIDS Rep. 3 (2006) 66-73
25. Abbas A.K., Lichtman A.H., and Pober J.S. Cellular and Molecular Immunology. IV ed. (2005), WB Saunders Co., Philadelphia